A ground breaking early detection platform focused on women’s health
A ground breaking early detection platform focused on women’s health
Our revolutionary tumor marker ganglioside platform is paving the way for life-saving early cancer detection
A novel blood test harnessing the power of tumor marker gangliosides to detect early-stage ovarian cancer
AOA Dx is pioneering the field of glycolipids through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. AOA Dx is developing the first and only technology utilizing these markers with data science, providing remarkable insights into early cancer detection.
Devoted to innovation in women’s health, AOA Dx is a team of industry experts and entrepreneurs committed to bringing impactful and cost-effective medical technologies from research and development into the hands of providers and patients.
Do you want to be a part of transforming women's health through early cancer detection?
We’re looking for teammates dedicated to raising the bar in women’s health.
